SEARCH

SEARCH BY CITATION

References

  • 1
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 61929.
  • 2
    Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18427.
  • 3
    McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 135864.
  • 4
    Poterucha JJ, Wiesner RH. Liver transplantation and hepatitis B. Ann Intern Med 1997; 126: 8057.
  • 5
    O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. J Hepatol 1992; 14: 10414.
  • 6
    Feray C, Zignego AL, Samuel D et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection: the liver transplantation model. Transplantation 1990; 49: 11558.
  • 7
    Ilan Y, Galun E, Nagler A, Baruch Y, Livni N, Tur-Kaspa R. Sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation. Liver Transplant Surg 1996; 2: 20610.
  • 8
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 165761.
  • 9
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 84959.
  • 10
    Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 884: 12125.
  • 11
    Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R. Beneficial effects of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997; 63: 3936.
  • 12
    Perrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 15816.
  • 13
    Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B infection in the United States. N Engl J Med 1999; 341: 125663.
  • 14
    Lai CL, Chien RN, Leung NW et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 618.
  • 15
    Lau DTY. Long-term lamivudine therapy for chronic hepatitis B. Antiviral Ther 2000; 5: 4366.
  • 16
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transplant 2001; 7: 1137.
  • 17
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV DNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 7147.
  • 18
    Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 7113.
  • 19
    Tur-Kaspa R, Klein A, Aharonson SH. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992; 16: 133842.
  • 20
    Bain VG, Kneteman NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 145662.
  • 21
    Kitay-Cohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis. Transplantation 2000; 69: 23823.
  • 22
    Yao F, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 3017.
  • 23
    Sponseller CA, Bacon BR, DiBisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. Liver Transplant 2000; 6: 71520.
  • 24
    Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 202.
  • 25
    Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 16707.
  • 26
    Niesters HG, Honkoop P, Haagsma EB, De Man RA, Schalm SW, Osterhaus AD. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177: 13825.
  • 27
    Seta T, Yokosuka O, Imazeki F, Tagawa M, Saisho H. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000; 60: 816.
  • 28
    Nery JR, Weppler D, Rodriguez M, Ruiz PH, Schiff ER, Tzakis A. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 161521.
  • 29
    Andreone P, Caraceni P, Grazi GL et al. Lamivudine treatment for acute hepatitis B after transplantation. J Hepatol 1998; 29: 9859.
  • 30
    Dodson SF, Balan V, Shakil O, Bonham A, Rakela J, Fung JJ. Lack of efficacy of lamivudine for HBV infection after liver transplantation. Hepatology 1998; 28: 262A.
  • 31
    McCaughan GW, Spencer J, Koorey D et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immunoglobulin. Liver Transplant 1999; 5: 5129.
  • 32
    Malkan G, Cattral MS, Humar A et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69: 14037.
  • 33
    Seehofer D, Rayes N, Berg T et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int 2000; 13: 2906.
  • 34
    Fontana RJ, Hann HW, Wright T et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transplant 2001; 7: 50410.
  • 35
    Chu CJ, Fontana RJ, Moore C et al. Outcome of liver transplantation of hepatitis B: report of a single center experience. Report of a single center experience. Liver Transplant, 2001: 7: 72431.
  • 36
    Atkins M, Hunt CM, Brown N et al. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 1998; 28: 319A.
  • 37
    Benhamou Y, Bochet M, Thibault V et al. Long term incidence of hepatitis B resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 13026.
  • 38
    Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 162731.
  • 39
    Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398402.
  • 40
    Ben-Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68: 2326.
  • 41
    Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 10713.
  • 42
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 56772.
  • 43
    Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy. Hepatology 1998; 27: 17116.
  • 44
    Xiong X, Flores C, Yang H, Toole J, Gibbs C. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 166973.
  • 45
    Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 12934.
  • 46
    Gow PJ, Mutimer DJ. De novo hepatitis B infection acquired during liver transplantation. Q J Med 2001; 94: 2715.
  • 47
    Dodson SF. Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors. Clin Transplant 2000; 14 (Suppl. 2): 204.
  • 48
    Fabia R, Levy MF, Crippin J et al. De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transplant Surg 1998; 4: 11927.
  • 49
    Crespo J, Fabrega E, Casafont F et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transplant Surg 1999; 5: 17583.
  • 50
    Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 21322.
  • 51
    Terrault NA, Zhou S, McCory RW et al. Incidence and clinical consequence of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28: 55561.
  • 52
    Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27: 25463.
  • 53
    Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 80915.
  • 54
    Lo CM, Cheung ST, Lai CL et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233: 27681.
  • 55
    The Lamivudine Transplant Group, Perrillo R, Wright T, Rakela J et al. A multicenter United States–Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 2001; 33: 42432.
  • 56
    Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 5859.
  • 57
    Terrault NA, Wright TL, Roberts JP, Ascher NL. Combined short-term hepatitis B immunoglobulin (HBGIg) and long-term lamivudine (LAM) versus HBIg monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients. Hepatology 1998; 28: 398A.
  • 58
    Keeffe EB. End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B. J Med Virol 2000; 61: 4038.
  • 59
    Dodson SF, De Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transplant 2000; 6: 4349.
  • 60
    Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplant 2000; 6: 7418.
  • 61
    Yoshida EM, Erb SR, Partovi N et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low dose hepatitis B immune globulin. Liver Transplant Surg 1999; 5: 5205.
  • 62
    Marzan A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 90310.
  • 63
    Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immunoglobulin for prophylaxis of hepatitis B reinfection after liver transplantation – possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895902.